Therapeutic potential of cannabinoids in glaucoma

T Lindner, D Schmidl, L Peschorn, V Pai… - Pharmaceuticals, 2023 - mdpi.com
Glaucoma is a leading cause of irreversible blindness worldwide. To date, intraocular
pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated …

Cannabinoids in glaucoma patients: The never-ending story

A Passani, C Posarelli, AT Sframeli, L Perciballi… - Journal of clinical …, 2020 - mdpi.com
Glaucoma is one of the principal causes of irreversible blindness worldwide. Yet, intraocular
pressure (IOP) is the main modifiable risk factor for disease progression. In the never-ending …

Cannabinoid applications in glaucoma

S Pinar-Sueiro, R Rodríguez-Puertas… - Archivos de la Sociedad …, 2011 - Elsevier
Introduction Glaucoma is a slowly progressive optic neuropathy that is one of the leading
causes of legal blindness throughout the world. Currently there is a limited group of topical …

The endocannabinoid system as a therapeutic target in glaucoma

EA Cairns, WH Baldridge, MEM Kelly - Neural plasticity, 2016 - Wiley Online Library
Glaucoma is an irreversible blinding eye disease which produces progressive retinal
ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk …

Cannabinoids in the treatment of glaucoma

T Järvinen, DW Pate, K Laine - Pharmacology & therapeutics, 2002 - Elsevier
The leading cause of irreversible blindness is glaucoma, a disease normally characterized
by the development of ocular hypertension and consequent damage to the optic nerve at its …

Cannabinoids and glaucoma

I Tomida, RG Pertwee, A Azuara-Blanco - British journal of …, 2004 - bjo.bmj.com
Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse
therapeutic possibilities, new and better treatments for glaucoma are highly desirable …

The arguments for and against cannabinoids application in glaucomatous retinopathy

Y Panahi, A Manayi, M Nikan, M Vazirian - Biomedicine & …, 2017 - Elsevier
Glaucoma represents several optic neuropathies leading to irreversible blindness through
progressive retinal ganglion cell (RGC) loss. Reduction of intraocular pressure (IOP) is …

Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists

BD Hudson, M Beazley, AM Szczesniak… - … of Pharmacology and …, 2011 - ASPET
Intraocular pressure (IOP) is the primary risk factor for glaucoma, a blinding eye disease.
Cannabinoid agonists have long been known to decrease IOP, suggesting they may be …

Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection

C Nucci, M Bari, A Spanò, MT Corasaniti… - Progress in brain …, 2008 - Elsevier
Recent evidence shows that the endocannabinoid system is involved in the pathogenesis of
numerous neurodegenerative diseases of the central nervous system. Pharmacologic …

Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit

MA Elsohly, EC Harland, DA Benigni… - Current eye …, 1984 - Taylor & Francis
Thirty-two different cannabinoids were tested for their ability to reduce intraocular pressure
(IOP) in the rabbit. These included many of Δ9-and Δ8-THC derivatives and metabolites …